We are live on
!
Find out more
CYTH
Cyclo Therapeutics, Inc. Common Stock
CYTH
CYTH
Delisted
CYTH was delisted on the 25th of March, 2025.
13 hedge funds and large institutions have $1.38M invested in Cyclo Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
13% less funds holding
Funds holding: 15 → 13 (-2)
19% less capital invested
Capital invested by funds: $1.71M → $1.38M (-$332K)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Holders
13
Holders Change
-2
Holders Change %
-13.33%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
6
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$33.2K |
| 2 |
BlackRock
New York
|
+$15.2K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$7.03K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.13K |
| 5 |
Citigroup
New York
|
+$4.31K |
Top Sellers
| 1 |
VF
Virtu Financial
New York
|
-$83K |
| 2 |
Two Sigma Advisers
New York
|
-$38K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$37.1K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$3K |
| 5 |
Morgan Stanley
New York
|
-$1.05K |